Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology ...
18 May 2017 - 7:05AM
Business Wire
- Clinical and Biomarker Correlates of
Outcomes in ZUMA-1 Pivotal Trial of axicabtagene ciloleucel in
Refractory, Aggressive Non-Hodgkin Lymphoma (NHL)
- Updated Efficacy and Safety Data from
ZUMA-3, a Phase 1/2 study of KTE-C19 in Adult Patients with
Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- Health Economics and Outcomes Research
Abstract on Current Treatment Cost for Diffuse Large B-Cell
Lymphoma (DLBCL)
Kite Pharma, Inc. (Nasdaq:KITE) today announced new data
presentations from multiple studies related to its lead
investigational candidate, axicabtagene ciloleucel (also known as
KTE-C19), at the 2017 American Society of Clinical Oncology (ASCO)
Annual Meeting in Chicago, IL, June 2-6, 2017. The full text for
abstracts is available online through the ASCO website at
http://abstracts.asco.org.
“The presentations at ASCO continue to enhance our growing
knowledge on the potential for cell therapy,” said David Chang,
M.D., Ph.D., Executive Vice President of Research and Development
and Chief Medical Officer of Kite. “The translational insights from
these data presentations are invaluable as we advance axicabtagene
ciloleucel/KTE-C19 and seek to optimize treatment, not only in NHL,
but also across a broad range of hematologic malignancies.”
Poster Discussion:
Clinical and biologic covariates of outcomes in ZUMA-1: a
pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in
patients with refractory aggressive non-Hodgkin lymphoma
(r-NHL)
- Abstract #7512
- Session: Poster Session: Hematologic
Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
- Poster Board #274
- Session Time/Location: Monday, June 5,
2017: 8:00-11:30 AM CDT, Hall A
- Poster Discussion Session
Time/Location: Monday, June 5, 2017: 1:15-2:30 PM CDT, E354b
- Presenter: Frederick L. Locke, M.D.,
Moffitt Cancer Center, Tampa, FL
Poster Presentations
Updated results from ZUMA-3, a phase 1/2 study of KTE-C19
chimeric antigen receptor (CAR) T cell therapy, in adults with
high-burden relapsed/refractory acute lymphoblastic leukemia (R/R
ALL)
- Abstract #3024
- Session: Poster Session: Developmental
Therapeutics - Immunotherapy
- Poster Board #119
- Session Time/Location: Monday, June 5,
2017: 8:00-11:30 AM CDT, Hall A
- Presenter: Bijal D. Shah, M.D., Moffitt
Cancer Center, Tampa, FL
Product characteristics associated with in vivo expansion of
anti-CD19 CAR T cells in patients treated with axicabtagene
ciloleucel (axi-cel)
- Abstract #3023
- Session: Poster Session: Developmental
Therapeutics – Immunotherapy
- Poster Board #118
- Session Time/Location: Monday, June 5,
2017: 8:00-11:30 AM CDT, Hall A
- Presenter: Frederick L. Locke, M.D.,
Moffitt Cancer Center, Tampa, FL
Characterization of anti-CD19 chimeric antigen receptor (CAR)
T cell-mediated tumor microenvironment immune gene profile in a
multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel,
KTE-C19)
- Abstract #3025
- Session: Poster Session: Developmental
Therapeutics - Immunotherapy
- Poster Board #120
- Session Time/Location: Monday, June 5,
2017: 8:00-11:30 AM CDT, Hall A
- Presenter: Jerome Galon, Ph.D.,
Laboratory of Integrative Cancer Immunology, INSERM
ZUMA-6: Phase 1-2 multicenter study evaluating safety
and efficacy of axicabtagene ciloleucel (axi-cel; KTE-C19) in
combination with atezolizumab in patients with refractory diffuse
large B-cell lymphoma (DLBCL)
- Abstract #TPS7572
- Session: Trials in Progress Poster
Session: Hematologic Malignancies – Lymphoma and Chronic
Lymphocytic Leukemia
- Poster Board #331a
- Session Time/Location: Monday, June 5,
2017: 8:00-11:30 AM CDT, Hall A
- Presenter: Frederick L. Locke, M.D.,
Moffitt Cancer Center, Tampa, FL
Online Publication
Total 1-year cost of diffuse large B-cell lymphoma (DLBCL)
beyond first-line (1L) therapy: A retrospective cohort
analysis
- Abstract # e18333
- Senior Author: Anna Purdum, PharmD,
M.S., Kite Pharma
About axicabtagene ciloleucel
Kite’s lead product candidate, axicabtagene ciloleucel,
previously known as KTE-C19, is an investigational therapy in which
a patient's T cells are engineered to express a chimeric antigen
receptor (CAR) to target the antigen CD19, a protein expressed on
the cell surface of B-cell lymphomas and leukemias, and redirect
the T cells to kill cancer cells. Axicabtagene ciloleucel has been
granted Breakthrough Therapy Designation status for diffuse large
B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and
primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food
and Drug Administration (FDA) and Priority Medicines (PRIME)
regulatory support for DLBCL in the EU.
About Kite
Kite is a biopharmaceutical company engaged in the development
of innovative cancer immunotherapies with a goal of providing
rapid, long-term durable response and eliminating the burden of
chronic care. The company is focused on chimeric antigen receptor
(CAR) and T cell receptor (TCR) engineered cell therapies designed
to empower the immune system's ability to recognize and kill
tumors. Kite is based in Santa Monica, CA. For more
information on Kite, please visit www.kitepharma.com. Sign up
to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the ability to advance axicabtagene
ciloleucel/KTE-C19 and optimize treatment in NHL and across a broad
range of hematologic malignancies. Various factors may cause
differences between Kite's expectations and actual results as
discussed in greater detail in Kite's filings with the Securities
and Exchange Commission, including without limitation in its Form
10-Q for the quarter ended March 31, 2017. Any forward-looking
statements that are made in this press release speak only as of the
date of this press release. Kite assumes no obligation to update
the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170517006347/en/
Kite Pharma, Inc.Christine CassianoSVP, Corporate Communications
& Investor Relationsccassiano@kitepharma.comorGreg MannVP,
Investor Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Apr 2024 to May 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From May 2023 to May 2024